• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

脂质体两性霉素B在患者体内的药代动力学和耐受性

Pharmacokinetics and tolerance of liposomal amphotericin B in patients.

作者信息

Gokhale P C, Barapatre R J, Advani S H, Kshirsagar N A, Pandya S K

机构信息

Department of Pharmacology, Seth G.S. Medical College, Bombay, India.

出版信息

J Antimicrob Chemother. 1993 Jul;32(1):133-9. doi: 10.1093/jac/32.1.133.

DOI:10.1093/jac/32.1.133
PMID:8226404
Abstract

Amphotericin B incorporated into small unilamellar liposomes prepared from soya phosphatidylcholine and cholesterol in a molar ratio of 7:3 was administered to 12 patients with suspected or documented systemic fungal infection. Each patient received 0.1, 0.4 and 1.0 mg/kg dose of liposomal amphotericin B. Liposomal amphotericin B was well tolerated by these patients with no dose-limiting toxicity. Mild to moderate fever with rigors occurred in 3 patients after the higher doses. Peak plasma amphotericin B concentrations, measured by HPLC; were 0.747-1.429 mg/L and 24 h trough concentrations were 0.148-0.363 mg/L. The mean T1/2 beta of amphotericin B was 17.2 h with a mean volume of distribution of 2.285 L/kg. While these pharmacokinetic parameters obtained with this liposomal amphotericin B formulation are comparable to the values obtained after conventional amphotericin B therapy, they are strikingly different from values obtained by other workers using small unilamellar liposomes with either positive or negative charge. Yet in animal experiments the distribution of all formulations are comparable.

摘要

将两性霉素B包裹于由大豆磷脂酰胆碱和胆固醇按摩尔比7:3制备的小单层脂质体中,给予12例疑似或确诊为系统性真菌感染的患者。每位患者接受0.1、0.4和1.0mg/kg剂量的脂质体两性霉素B。这些患者对脂质体两性霉素B耐受性良好,无剂量限制性毒性。3例患者在接受较高剂量后出现轻度至中度寒战发热。通过高效液相色谱法测定,血浆两性霉素B峰值浓度为0.747 - 1.429mg/L,24小时谷浓度为0.148 - 0.363mg/L。两性霉素B的平均β半衰期为17.2小时,平均分布容积为2.285L/kg。虽然这种脂质体两性霉素B制剂获得的这些药代动力学参数与传统两性霉素B治疗后获得的值相当,但与其他研究人员使用带正电荷或负电荷的小单层脂质体获得的值显著不同。然而,在动物实验中,所有制剂的分布情况相当。

相似文献

1
Pharmacokinetics and tolerance of liposomal amphotericin B in patients.脂质体两性霉素B在患者体内的药代动力学和耐受性
J Antimicrob Chemother. 1993 Jul;32(1):133-9. doi: 10.1093/jac/32.1.133.
2
Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.脂质体两性霉素B用于持续发热和中性粒细胞减少患者的经验性治疗。美国国立过敏和传染病研究所真菌病研究组。
N Engl J Med. 1999 Mar 11;340(10):764-71. doi: 10.1056/NEJM199903113401004.
3
Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.两性霉素B负载免疫调节剂促吞噬肽脂质体在小鼠模型中的毒性、稳定性及药代动力学
J Antimicrob Chemother. 2006 Jul;58(1):125-32. doi: 10.1093/jac/dkl177. Epub 2006 May 18.
4
Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients.两性霉素B小单层脂质体制剂(安必素)在中性粒细胞减少患者中的安全性、耐受性及药代动力学
Antimicrob Agents Chemother. 1998 Sep;42(9):2391-8. doi: 10.1128/AAC.42.9.2391.
5
Antimycotic therapy with liposomal amphotericin-B for patients undergoing bone marrow or peripheral blood stem cell transplantation.对接受骨髓或外周血干细胞移植的患者采用脂质体两性霉素B进行抗真菌治疗。
Leuk Lymphoma. 1997 Feb;24(5-6):491-9. doi: 10.3109/10428199709055586.
6
Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report.脂质体两性霉素B成功治疗对两性霉素B耐药的播散性念珠菌病:1例报告
J Cancer Res Clin Oncol. 1993;119(10):569-71. doi: 10.1007/BF01372718.
7
Clinical experience with multilamellar liposomal amphotericin B in patients with proven and suspected fungal infections.
Scand J Infect Dis. 1993;25(4):487-96. doi: 10.3109/00365549309008531.
8
Liposomal amphotericin B. Therapeutic use in the management of fungal infections and visceral leishmaniasis.脂质体两性霉素B。在真菌感染和内脏利什曼病治疗中的应用。
Drugs. 1998 Apr;55(4):585-612. doi: 10.2165/00003495-199855040-00008.
9
Clinical use of liposomal and lipid-complexed amphotericin B.脂质体和脂质复合两性霉素B的临床应用。
J Antimicrob Chemother. 1994 May;33(5):907-16. doi: 10.1093/jac/33.5.907.
10
Liposomal amphotericin B for the treatment of severe fungal infection.脂质体两性霉素B治疗严重真菌感染。
Dynamics. 2001 Spring;12(1):17-21.

引用本文的文献

1
Defining breakthrough invasive fungal infection-Position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology.定义突破性侵袭性真菌感染——医学真菌学研究组教育和研究联盟及欧洲医学真菌学会联合会立场文件。
Mycoses. 2019 Sep;62(9):716-729. doi: 10.1111/myc.12960. Epub 2019 Jul 19.
2
Comparative efficacy, toxicity and biodistribution of the liposomal amphotericin B formulations Fungisome and AmBisome in murine cutaneous leishmaniasis.脂质体两性霉素 B 制剂 Fungisome 和 AmBisome 在小鼠皮肤利什曼病中的比较疗效、毒性和生物分布。
Int J Parasitol Drugs Drug Resist. 2018 Aug;8(2):223-228. doi: 10.1016/j.ijpddr.2018.04.001. Epub 2018 Apr 12.
3
Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients.
抗真菌药物的药代动力学:优化患者治疗的实际意义。
Infection. 2017 Dec;45(6):737-779. doi: 10.1007/s15010-017-1042-z. Epub 2017 Jul 12.
4
Optimizing efficacy of amphotericin B through nanomodification.通过纳米修饰优化两性霉素B的疗效。
Int J Nanomedicine. 2006;1(4):417-32. doi: 10.2147/nano.2006.1.4.417.
5
Carrier effects on biological activity of amphotericin B.载体对两性霉素B生物活性的影响。
Clin Microbiol Rev. 1996 Oct;9(4):512-31. doi: 10.1128/CMR.9.4.512.
6
Successful treatment of disseminated candidiasis resistant to amphotericin B by liposomal amphotericin B: a case report.脂质体两性霉素B成功治疗对两性霉素B耐药的播散性念珠菌病:1例报告
J Cancer Res Clin Oncol. 1993;119(10):569-71. doi: 10.1007/BF01372718.
7
Susceptibility testing of Candida albicans and Aspergillus species by a simple microtiter menadione-augmented 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide assay.通过简单的微量滴定甲萘醌增强的3-(4,5-二甲基-2-噻唑基)-2,5-二苯基-2H-溴化四唑测定法对白色念珠菌和曲霉菌进行药敏试验。
J Clin Microbiol. 1995 Mar;33(3):661-7. doi: 10.1128/jcm.33.3.661-667.1995.